IP Library › Granted Patent US 11,395,798
Granted Patent B2
US 11,395,798 · App. 15/765,900 · Granted Jul 26, 2022

O/W type emulsion

Inventors: Kota Tange (Kawasaki, JP); Yuta Nakai (Kawasaki, JP); Hidetaka Akita (Sapporo, JP); Hiroki Tanaka (Sapporo, JP); Ayaka Watanabe (Sapporo, JP); Naoya Miura (Sapporo, JP); Hideyoshi Harashima (Sapporo, JP)
Assignees: NOF CORPORATION; NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
A61K9/107A61K9/1075A61K31/37A61K31/573A61K31/575A61K47/20A61K47/22A61K47/24A61K47/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,395,798
App. No.
15/765,900
Granted
Jul 26, 2022
Kind
B2
Abstract

The present invention provides an O/W type emulsion having a volume median diameter of not more than 100 nm and containing a compound represented by the formula (1) wherein X a and X b are each independently X 1 , X 2 or a 1,4-piperazinediyl group; s is 1 or 2, R 4 is an alkyl group having 1-6 carbon atoms, n a and n b are each independently 0 or 1, R 1a , R 1b , R 2a and R 2b are each independently an alkylene group having 1-6 carbon atoms, Y a and Y b are each independently an ester bond, or the like, and R 3a and R 3b are each independently a liposoluble vitamin residue or the like.

Claims (21)

1. An O/W type emulsion having a volume median diameter of not more than 100 nm and comprising a compound represented by the formula (1)

wherein X a and X b are each independently X 1 , X 2 or 1,4-piperazinediyl group;

s is 1 or 2,

R 4 is an alkyl group having 1-6 carbon atoms,

n a and n b are each independently 0 or 1,

R 1a and R 1b are each independently an alkylene group having 1-6 carbon atoms,

R 2a a and R 2b are each independently an alkylene group having 1-6 carbon atoms,

Y a and Y b are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond,

R 3a and R 3b are each independently a sterol residue, a liposoluble vitamin residue or an aliphatic hydrocarbon group having 12-23 carbon atoms,

the sterol residue is a residue derived from cholesterol, cholestanol, stigmasterol, β-sitosterol, lanosterol, ergosterol, cholesterol hemisuccinate, or cholesterol hemiglutarate, and

the liposoluble vitamin residue is a residue derived from retinoic acid, retinol, retinal, ergosterol, 7-dehydrocholesterol, calciferol, cholecalciferol, dihydroergocalciferol, dihydrotachysterol, tocopherol, tocotrienol, tocopherol hemisuccinate, or tocopherol hemiglutarate, and

encapsulating a drug having a water/octanol distribution coefficient Log Pow of not less than 5.

2. The O/W type emulsion according to claim 1 , wherein the volume median diameter is 30-50 nm.

3. The O/W type emulsion according to claim 1 , further comprising at least one selected from the group consisting of phospholipid, cholesterol and PEG lipid.

4. The O/W type emulsion according to claim 1 , wherein the drug is 4-methylumbelliferone cholesterol hemisuccinate or dexamethasone cholesterol hemisuccinate.

5. A method for delivering a drug having a water/octanol distribution coefficient Log Pow of not less than 5 into a cell, comprising contacting the O/W type emulsion according to claim 1 with the cell.

6. The method according to claim 5 , wherein the O/W type emulsion is brought into contact with the cell in vitro.

7. The method according to claim 5 , wherein the O/W type emulsion is brought into contact with the cell by administration to a body.

8. The O/W type emulsion according to claim 2 , wherein the drug is 4-methylumbelliferone cholesterol hemisuccinate or dexamethasone cholesterol hemisuccinate.

9. The O/W type emulsion according to claim 2 , further comprising at least one selected from the group consisting of phospholipid, cholesterol and PEG lipid.

10. The O/W type emulsion according to claim 9 , wherein the drug is 4-methylumbelliferone cholesterol hemisuccinate or dexamethasone cholesterol hemisuccinate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2018
From: TANGE, KOTA; NAKAI, YUTA; AKITA, HIDETAKA; TANAKA, HIROKI; WATANABE, AYAKA; MIURA, NAOYA; HARASHIMA, HIDEYOSHI
To: NOF CORPORATION; NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
Reel/Frame 045437/0652 →
Priority Claims (1)
JP JP2015-200148 · Oct 8, 2015 · national
Continuity (1)
Related Publication 20190110986A1 · Apr 18, 2019